Role of β-microseminoprotein from prostate cancer initiation to recurrence: A mini-review

Table 3 Relative β-microseminoprotein levels measured from urine and serum of prostate cancer patients undergone various treatments

	Treatment type (number of patients)	Mean (range)	Estimate (95%CI)	P
[Urine MSMB]:[Serum MSMB]	ADT (8)	1.397 (0.163-119.5)	0.396 (0.085-1.852)	0.227
	ADT and RT (9)	4.100 (0.989-50.50)	1.162 (0.19-7.099)	0.866
	RT (5)	25.00 (10.32-45.88)	7.089 (1.16-43.322)	0.035
	AS (5)	3.529 (0.746-70.32)	1
[Urine MSMB]	ADT (8)	1.908 (0.639-80.88)	0.172 (0.04-0.741)	0.020
	ADT and RT (9)	1.677 (0.579-35.73)	0.151 (0.027-0.839)	0.032
	RT (5)	43.12 (16.73-83.51)	3.879 (0.698-21.57)	0.116
	AS (5)	11.11 (2.186-160.3)	1
[Serum MSMB]	ADT (8)	1.366 (0.560-25.92)	0.434 (0.145-1.301)	0.129
	ADT and RT (9)	0.409 (0.081-0.720)	0.13 (0.036-0.471)	0.003
	RT (5)	1.723 (0.730-8.093)	0.547 (0.151-1.986)	0.343
	AS (5)	3.149 (0.624-10.21)	1

Log-transformed β-microseminoprotein measurements were used in the analysis and the results presented above were determined by using the exponential (antilog) function. Generalised linear model was carried out to investigate MSMB level variability among four different treatments. All analyses were carried out using statistical package R[99] and SAS (V9.1 SAS Institute, Cary, NC, United States). ADT: Androgen deprivation therapy; RT: Radiation therapy; AS: Active surveillance.